Grand Pharmaceutical Group Completes Enrollment in Phase III Study for Ryaltris Nasal Spray
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the completion of all subject enrollment...
Clinical trial approval / initiation
Alphamab Oncology and CSPC Pharma Get Green Light for KN026 Phase III Study in Breast Cancer
China-based Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) have announced receiving...
Jiangsu Hengrui Pharmaceuticals Advances SHR-1819, SHR-2002, and Adebrelimab into New Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced receiving clinical trial approvals for its...
Ascletis Pharma Receives Approval for Phase IIa Study of ASC10 for RSV Infection
China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving the green light to conduct a...
Henlius Biotech’s HLX26 and HaiSiZhuang Combo for NSCLC Gets NMPA Phase II Approval
Shanghai Henlius Biotech (HKG: 2696) has announced that it has received approval from the National...
Yantai Dongcheng Pharma’s 177Lu-LNC1003 Cleared for US FDA Phase I Study
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that it has received...
ABM Therapeutics’ ABM-168 Begins Phase I Dosing in the US for Advanced Solid Tumors
Shanghai-based ABM Therapeutics, Inc. has announced the commencement of the first patient enrollment and dosing...
CARsgen Therapeutics’ AB011 and Tecentriq Combo Gets NMPA Approval for Gastric Cancer Treatment
China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...
BDgene Technology’s BD111 Receives Tacit Approval for HSV-1 Keratitis Trial
Shanghai BDgene Technology Co., Ltd has announced that it has received tacit clinical trial approval...
TYK Medicines’ TY-9591 Gains CDE Green Light for Pivotal Phase II Study in NSCLC with Brain Metastases
Shanghai-based TYK Medicines has announced that it has received the green light from the Center...
CMS Receives NMPA Approval for Clinical Study of Tetravalent BsAb for nAMD
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received approval from...
Sirnaomics’ RV-1730 Receives FDA Clearance for Phase I COVID-19 Vaccine Booster Trial
Sirnaomics Ltd (HKG: 2257) has announced that it has received clearance from the United States...
SynerK Achieves Milestone with First Patient Dosing in Phase I siRNA Clinical Trial
SynerK, a developer of RNA-targeted therapies with operations in Boston, US, and Beijing and Suzhou,...
Zelgen Biopharmaceuticals’ ZG2001 Receives US FDA Clinical Trial Approval for Pan-KRAS Inhibitor
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...
Sichuan Biokin Pharmaceutical Gets NMPA Approval for Two Clinical Studies on Cancer Therapies
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced receiving approval...
Evopoint Biosciences Gets CDE Approval for Phase I/II Study of XNW27011 ADC
Suzhou Evopoint Biosciences Co., Ltd., a China-based pharmaceutical company, has announced receiving approval from the...
Reistone Biopharma’s RSS0343 Receives NMPA Approval for Non-Cystic Fibrosis Bronchiectasis
Reistone Biopharma Co., Ltd, a company incubated by Hengrui Pharmaceuticals (SHA: 600276) with an investment...
Neurodawn Pharmaceutical’s Y-1 Receives NMPA Approval for Primary Intracranial Tumor Treatment
Nanjing-based Neurodawn Pharmaceutical Co., Ltd has announced that its Category 1 drug, injectable Y-1, has...
Jiangxi Jemincare Group Secures Clinical Trial Approvals for Four Innovative Drugs
Jiangxi Jemincare Group, a China-based pharmaceutical company, has announced receiving clinical trial approvals for four...
CSPC Pharmaceutical Group Gets NMPA Approval for SYS6010 ADC Clinical Trial
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial...